Ipsen to acquire Albireo accelerating growth in rare disease with treatments for several pediatric liver diseases
Ipsen and Albireo announced that they have entered into a definitive merger agreement under which Ipsen will acquire Albireo, a leading innovator in bile-acid modulators to treat pediatric and adult cholestatic liver diseases.
France General United States United Kingdom Vastra Gotalands Lan Mecklenburg Vorpommern Colleen Alabiso
Source: ipsen.com